BeOne Medicines (BEIGF) Depreciation & Amortization (CF) (2015 - 2026)

BeOne Medicines (BEIGF) has 12 years of Depreciation & Amortization (CF) data on file, last reported at $41.1 million in Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $41.1 million, up 25.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $150.0 million (down 16.31% YoY), and the FY2025 annual result was $141.7 million, down 17.51% from the prior year.
• Depreciation & Amortization (CF) climbed to $41.1 million in Q1 2026 per BEIGF's latest filing, from $36.0 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $71.3 million in Q3 2024 and troughed at $15.5 million in Q2 2022.
• A 5-year average of $29.9 million and a median of $24.9 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2024 and 2025: Depreciation & Amortization (CF) soared 231.44% in 2024, then sank 47.7% in 2025.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $18.0 million in 2022, then surged by 32.21% to $23.8 million in 2023, then surged by 110.95% to $50.2 million in 2024, then declined by 28.38% to $36.0 million in 2025, then increased by 14.34% to $41.1 million in 2026.
• Business Quant data shows BEIGF's Depreciation & Amortization (CF) at $41.1 million in Q1 2026, $36.0 million in Q4 2025, and $37.3 million in Q3 2025.